Phase 2 study of pevonedistat (P) plus azacitidine (A) versus azacitidine in patients (pts) with higher-risk myelodysplastic syndromes (MDS)/chronic myelomonocytic leukemia (CMML) or low-blast acute myelogenous leukemia (LB-AML) (NCT02610777)
ONCOLOGY RESEARCH AND TREATMENT(2020)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要